- Home
- PROK vs PFL Comparison
PROK vs PFL Comparison
Compare PROK & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- PFL
- Stock Information
- Founded
- PROK 2015
- PFL 2003
- Country
- PROK United States
- PFL United States
- Employees
- PROK N/A
- PFL N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- PFL Finance Companies
- Sector
- PROK Health Care
- PFL Finance
- Exchange
- PROK Nasdaq
- PFL Nasdaq
- Market Cap
- PROK 417.1M
- PFL 374.5M
- IPO Year
- PROK N/A
- PFL N/A
- Fundamental
- Price
- PROK $2.78
- PFL $8.46
- Analyst Decision
- PROK Strong Buy
- PFL
- Analyst Count
- PROK 4
- PFL 0
- Target Price
- PROK $6.25
- PFL N/A
- AVG Volume (30 Days)
- PROK 1.5M
- PFL 113.7K
- Earning Date
- PROK 11-10-2025
- PFL 01-01-0001
- Dividend Yield
- PROK N/A
- PFL 11.53%
- EPS Growth
- PROK N/A
- PFL N/A
- EPS
- PROK N/A
- PFL N/A
- Revenue
- PROK $744,000.00
- PFL N/A
- Revenue This Year
- PROK $471.74
- PFL N/A
- Revenue Next Year
- PROK N/A
- PFL N/A
- P/E Ratio
- PROK N/A
- PFL N/A
- Revenue Growth
- PROK N/A
- PFL N/A
- 52 Week Low
- PROK $0.46
- PFL $6.98
- 52 Week High
- PROK $7.13
- PFL $8.62
- Technical
- Relative Strength Index (RSI)
- PROK 45.61
- PFL 51.25
- Support Level
- PROK $2.56
- PFL $8.38
- Resistance Level
- PROK $2.94
- PFL $8.49
- Average True Range (ATR)
- PROK 0.23
- PFL 0.05
- MACD
- PROK -0.05
- PFL 0.01
- Stochastic Oscillator
- PROK 25.41
- PFL 75.03
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.